Do you want to read an article? Please log in or register.
Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-related Macular Degeneration: A Phase 3 Randomized Trial
Macular Diseases
Related content
Macular Diseases
Intravitreal Aflibercept 8 mg in Neovascular Age-related Macular Degeneration: 96-Week Results from the Randomized Phase 3 PULSAR Trial
Ophthalmology
Korobelnik JF, Lanzetta P, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Sun X, Berliner AJ, Schulze A, Zhao M, Schmelter T, Schmidt-Ott U, Zhang X, Morgan-Warren P, Hasanbasic Z, Vitti R, Chu KW, Reed K, Bhore R, Cheng Y, Bai Z, Hirshberg B, Yancopoulos GD, Wong TY, PULSAR investigators
doi: 10.1016/j.ophtha.2025.08.022
Macular DiseasesRetinal Diseases
Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial
Br J Ophthalmol
Agostini HT, Silva R, Holz FG, Larsen M, Altay L, Souied EH, Quiering C, Rose U, Liakopoulos S, SALT study group
doi: 10.1136/bjo-2024-326526
Macular Diseases
Long-Term Efficacy and Safety of CT-P42 in Patients with Diabetic Macular Edema: 52-Week Results from a Phase 3 Randomized Clinical Trial
Ophthalmol Ther
Brown DM, Wolf S, Veselovsky M, Veith M, Papp A, Mange S, Mondal LK, Romanczak D, Janco L, Chauhan R, Romanowska-Dixon B, Eremina A, Dusova J, Sagong M, Kim S, Bae Y, Kim S, Bae Y, Son D, Kang H, Choi S, Stanga PE
doi: 10.1007/s40123-025-01197-w
Macular Diseases
Efficacy and safety of brolucizumab every 6 weeks induction therapy for neovascular age-related macular degeneration
Sci Rep
Honda S, Maruyama-Inoue M, Otsuji T, Kyo A, Kobayashi Y, Yamamoto Y, Gomi F
doi: 10.1038/s41598-025-89638-1
Macular Diseases
Tissue Plasminogen Activator or Perfluoropropane for Submacular Hemorrhage in Age-Related Macular Degeneration: A Factorial Randomized Clinical Trial
JAMA Ophthalmol
Murphy GSP, Saleh A, Ayis S, Cheema MR, Mehta A, Steel DH, Membrey L, Costen M, Jackson TL
doi: 10.1001/jamaophthalmol.2024.4297
RECOMMENDED
Macular DiseasesFurther Publications
Cocoa Flavanol Supplementation and Risk of Age-Related Macular Degeneration: An Ancillary Study of the COSMOS Randomized Clinical Trial
★ 1
Recommended by
Prof. emer. Dr Josef Flammer, Faculty Member
JAMA Ophthalmol
Christen WG, Rist PM, Moorthy MV, Smith DC, Holman B, Clar A, Glynn RJ, Mares JA, Sobrin L, Shadyab AH, Allison MA, Millen AE, Manson JE, Sesso HD, COSMOS Research Group
doi: 10.1001/jamaophthalmol.2025.0353
Macular Diseases
TALON Phase IIIb Study: 32 Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age Related Macular Degeneration
Ophthalmol Retina
Regillo C, Kaiser PK, Kertes PJ, Gillies M, Maio-Twofoot T, D'Souza D, Guenther S, Lawrence D, Holz FG
doi: 10.1016/j.oret.2025.05.030
Macular Diseases
Treatment Regimens with Ranibizumab in Neovascular Age-Related Macular Degeneration: Real-World Results from the PACIFIC Study
Clin Ophthalmol
Lorenz K, Haritoglou C, Barthelmes D, Sefat AMM, Berk H, Beeke E, Scheffler M, Iwersen M, Müller B, Ziemssen F, members of the PACIFIC study group
doi: 10.2147/OPTH.S512630
Macular Diseases
Omega-3 Fatty Acids as Protective Factors for Age-related Macular Degeneration: Prospective Cohort and Mendelian Randomization Analyses
Ophthalmology
Xue CC, Li H, Yu M, Chong CCY, Fan Q, Tham YC, Cheung CMG, Wong TY, Chew EY, Cheng CY
doi: 10.1016/j.ophtha.2024.12.005